A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course

Summary

The purpose of this study is to make laquinimod 0.6 mg available for all subjects who completed the placebo-controlled MS-LAQ-301 study according to the protocol and to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis.

Timeline

Start

2009-11-10

Primary completion

2017-07-01

Completion

2017-07-01

Drugs

Indications